27th German Cancer Congress Berlin 2006
German Cancer Society (Frankfurt/M.)
22. - 26.03.2006, Berlin
Gynecologic Cancer
Meeting Abstract
(OP337)
[Full Text]
Financal calculation of a certified breast center – is there a the benefit?
Beckmann MW, Wagner S, Lux MP, Fasching PA, Universitätsbrustzentrum Franken[Full Text]
Meeting Abstract
(OP338)
[Full Text]
Improvement of prognosis of invasive ovarian cancer since 1988, especially in patients younger than 65 years of age: results of the Munich Cancer Registry
Hölscher G, Engel J, Hölzel D[Full Text]
Meeting Abstract
(OP339)
[Full Text]
Phase II trial of Docetaxel and Carboplatinum in recurrent platinum sensitive ovarian, peritoneal and tubal cancer - final results
Strauß HG, Henze A, Teichmann A, Karbe I, Baumgart A, Thomssen C, Kölbl H[Full Text]
Meeting Abstract
(OP340)
[Full Text]
A randomized multicenter Phase II study on neoadjuvant chemotherapy with Carboplatin and Docetaxel in advanced ovarian carcinomas (PRIMOVAR)
Park TW, Jänicke F, Ortmann O, Hilfrich J, Breitbach GP, Höss C, Möbus V, Dietrich K, Thomssen C, Kuhn W[Full Text]
Meeting Abstract
(OP341)
[Full Text]
Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102)
Belau AK, Huober J, Heilmann V, Mueller HH, Burges A, Pfisterer J, Gropp M, Schröder W, Wimberger P, du Bois A[Full Text]
Meeting Abstract
(OP342)
[Full Text]
First-line treatment of ovarian cancer FIGO stage IIB–IV using Paclitaxel/Carboplatin (TC) vs. Paclitaxel/Carboplatin followed by Topotecan (TOP): mature results of a gynecologic cancer intergroup phase III trial of the ago ovar and gineco
Jackisch C, Jackisch C, Pujade-Lauraine E, Olbricht S, Moebus V, Quaas J, Schade-Brittinger C, Richter B, Schroeder W, Lueck HJ, Pfisterer J[Full Text]
Meeting Abstract
(OP343)
[Full Text]
Prognostic significance of antibodies to HPV-16 – L1 Virus Like Partikels (VLP) in the sera of patients with invasive cervical cancer
Ackermann S, Mehlhorn G, Fasching PA, Skiba D, Beckmann MW[Full Text]
Meeting Abstract
(OP344)
[Full Text]
Expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with disease outcome
Gabriel B, zur Hausen A, Stickeler E, Dietz C, Gitsch G, Fischer DC, Bouda J, Tempfer C, Hasenburg A[Full Text]
Meeting Abstract
(OP345)
[Full Text]
Tspan-1 is strongly expressed by ovarian cancer cells
Deißler H, Scholz CJ, Sauer G, Koppold B, Kurzeder C, Kreienberg R, Deissler H[Full Text]
Meeting Abstract
(OP346)
[Full Text]
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, Schmalfeldt B, Diamandis EP, Schmitt M[Full Text]
Meeting Abstract
(OP347)
[Full Text]
Frequently Altered Expression of Wnt Antagonists DKK Family in Ovarian Cancer
An H, Schröter C, Bieker M, Rose F, Gross M, Niederacher D, Engenhart-Cabillic R, An H[Full Text]
Meeting Abstract
(PO348)
[Full Text]
Finaly analyzes of biweekly schedule of pegylated liposomal doxorubicin (PLD) in 64 heavily pretreated patients with relapsed ovarian cancer (ROC)
Sehouli J, Oskay-Oezcelik G, Kuehne J, Huindenburg H, Klare P, Heinrich G, Schmalfeldt B, Mertens H, Camara O, Lichtenegger W[Full Text]
Meeting Abstract
(PO349)
[Full Text]
Combination therapy with pegliposomal doxorubicin and carboplatin in malignant gynecologic tumours. A prospective multicenter phase-II trial of the AGO-OVAR and the AGO Kommission Uterus
Harter P, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Staehle A, Koelbl H, du Bois A[Full Text]
Meeting Abstract
(PO350)
[Full Text]
The Human Endogenous Retroviral gene Syncytin is induced in endometrial Hyperplasia by Tamoxifen via the Estrogen Receptor Pathway
Strick R, Ackermann S, Beckmann MW, Strissel PL[Full Text]
Meeting Abstract
(PO351)
[Full Text]
Phase II-Studie mit wöchentlich Docetaxel in Patientinnen mit fortgeschrittenem Endometriumkarzinom, AGO Uterus-4
Günthert A, Ackermann S, Kiesel L, Steiner E, Schröder W, Camara O, Mallmann P, Emons G[Full Text]
Meeting Abstract
(PO352)
[Full Text]
Caelyx 20 mg/m2 q2wks in platinum-refractory or early recurrent ovarian or peritoneal cancer - results from a phase II study
Persing M, Beau U, Kendzierski N, Karbe I, Strauss HG, Thomssen C[Full Text]
Meeting Abstract
(PO353)
[Full Text]
Expression of glycodelin in human ovarian cancer: immunohistochemistry and possible function
Jeschke U, Kunert-Keil C, Stahn R, Scholz C, Schumacher L, Janni W, Mylonas I, Schröder E, Kuhn C, Mayr D, Briese V, Friese K[Full Text]
Meeting Abstract
(PO354)
[Full Text]
Clinical relevance of selected biochemical parameter within amniotic fluid as markers of the disordered pregnancy and under special consideration of Zytokines and Tumormarkers
Albrecht S, Köhler S, Büttner R, Zimmermann T, Kamin G, Albrecht S, Distler W[Full Text]
Meeting Abstract
(PO355)
[Full Text]
Expression of inhibin/activin subunits (alpha, betaA and betaB) in normal and carcinogenic endometrial tissue: possible immunohistochemical differentiation markers
Worbs S, Shabani N, Mayr D, Dian D, Kuhn C, Jeschke U, Friese K, Mylonas I[Full Text]
Meeting Abstract
(PO356)
[Full Text]
A multicenter NOGGO-feasibility study of neoadjuvant concomitant radio-chemotherapy with curative intention in locally advanced cervical carcinoma
Köhler G, Belau A, Nehmzow M, Bartz K, Breitsprecher R[Full Text]
Meeting Abstract
(PO357)
[Full Text]
Polymorphism of IL-1 α, IL-1 β and IL-10 in patients with advanced ovarian cancer
Braicu EI, Pirvulescu C, Mustea A, Könsgen D, Sehouli J, Lichtenegger W[Full Text]
Meeting Abstract
(PO358)
[Full Text]
Prognostic Role of Expression of IL-1 a, IL-1 b, IL-1 Ra and IL-10 in Advanced Epithelial Ovarian Cancer (OC)
Pirvulescu C, Braicu EI, Mustea A, Könsgen D, Sehouli J[Full Text]
Meeting Abstract
(PO359)
[Full Text]
Prognostic impact of micrometasases in pelvic lymph nodes in patients with carcinoma of the cervix uteri
Horn LC, Peter D, Hentschel B, Bilek K[Full Text]
Meeting Abstract
(PO360)
[Full Text]
Prognostic significance of inhibin/activin subunits (alpha, betaA and betaB) in human endometrial carcinoma: an immunohistochemical analysis of 294 cases
Mylonas I, Worbs S, Shabani N, Darius D, Mayr D, Kuhn C, Schulze S, Kunze S, Sommer H, Jeschke U, Friese K[Full Text]
Meeting Abstract
(PO361)
[Full Text]
Localisation and prediction of lymph node metastases in ovarian cancer
Harter P, Gnauert K, Neugebauer B, Hils R, Buhrmann C, Traut A, Fisseler-Eckhoff A, du Bois A[Full Text]
Meeting Abstract
(PO362)
[Full Text]
Implementation of an interdisciplinary Online Tumor Conference as a new tool in the management of gynaecological cancers.
Chekerov R, Sehouli J, Schönerstedt-Zastrau K, Chekerov R, Böhmer D, Denkert C, Wieding A, Heinrich G, Ruhnke M, Lorsbach M, Lichtenegger W[Full Text]
Meeting Abstract
(PO363)
[Full Text]
HPV- infection in HIV-infected women as a tumor marker of recurrent cervical dyplasia
Gingelmaier A, Grubert T, Kästner R, Mylonas I, Weissenbacher T, Barthell E, Bergauer F, Friese K[Full Text]
Meeting Abstract
(PO364)
[Full Text]
Expression of HPV, steroid receptors and inhibin/activin subunits in diverse parts of endometroid adenocarcinoma with squamous differentiation
Gutsche S, Mylonas I, Shabani N, Kuhn C, Kunze S, Jeschke U, Friese K[Full Text]
Meeting Abstract
(PO365)
[Full Text]
Proliferation and Cell-Cell Fusion of Endometrial Carcinoma are induced by the Human Endogenous Retroviral Syncytin and regulated by TGF-β
Strick R, Ackermann S, Langbein M, Beckmann MW, Strissel PL[Full Text]
Meeting Abstract
(PO366)
[Full Text]
The results of a prospective study from expression of VEGF, VEGF-C, VEGF-D in patients with ovarian cancer
Sentschuk- Schmidt N, Mustea A, Koensgen D, Sehouli J, Lichtenegger W[Full Text]
Meeting Abstract
(PO367)
[Full Text]
Nutritional status of outpatients with gynaecologic cancer
Hollatz E, Kuhberg M, Loschen K, Sehouli J, Lichtenegger W[Full Text]
Meeting Abstract
(PE368)
[Full Text]
Management and course of histological verified cervical carcinoma in situ during pregnancy
Ackermann S, Mehlhorn G, Reissmann C, Beckmann MW[Full Text]
Meeting Abstract
(PE369)
[Full Text]
Feasibility and outcome of primary and adjuvant cervical cancer patients treatment with simultaneous Radio-Chemotherapy in an outpatient setting
Buhrmann C, Hils R, Prott FJ, Gnauert K, Traut A, du Bois A[Full Text]
Meeting Abstract
(PE370)
[Full Text]
Advanced Ovarian Cancer (OC) with Mainly Extraovarian Manifestation in a 22-Year Old Pregnant Patient: Diagnostic Issues
Belau AK, Bartz K, Hinken B, Schwesinger G, Koehler G[Full Text]
Meeting Abstract
(PE371)
[Full Text]
Prognostic impact of hemoglobin levels before and throughout a carboplatin/taxane-based chemotherapy on patients with primary epithelial ovarian cancer
Eichbaum M, Weiss L, Bruckner T, Gebauer G, Schneeweiss A, Fersis N, Sohn C[Full Text]
Meeting Abstract
(PE372)
[Full Text]
Ovarian Cancer Treatment Reality in Northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as the cause for inferior survival. A Retrospective Study of 139 Patients Receiving Chemotherapy and Palliative Care in an Oncology Group Practice.
Weide R, Arndt M, Pandorf A, Heymanns J, Thomalla J, Köppler H[Full Text]
Meeting Abstract
(PE373)
[Full Text]
Detection ofGene Amplification in Dysplastic Lesion of the Vulva and Cervix by FISH Analysis of Chromosome 3 - preliminary results
Gebauer G, Schleibaum J, Aulmann S, Sohn C, Sinn HP[Full Text]
Meeting Abstract
(PE374)
[Full Text]
Radiochemosensitivity testing (TRCA) in Gynecological Cancers
Albrecht S, Franz R, Zimmermann T, Doerfler A, Gatzweiler A, Distler W[Full Text]
Meeting Abstract
(PE375)
[Full Text]
Long term results of postoperative radiotherapy in carcinoma of the uterine cervix
Schüller P, Funk WK, Willich N[Full Text]
